Across 9 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Colgate-Palmolive Company news is Somewhat Bullish (+44)
on a scale from −100 to +100.
That is up 18 points from the previous 30 days (+26).
📈 India revenue rose 12.2% YoY to INR 1,705.7 crore in Q3 2026.
⚠️ EBITDA margin fell to 28% as brand spending outpaced earnings growth.
Bullish +65
Colgate-Palmolive India stock set for INR 24 interim dividend
AI-generated analysis
Key insights
📈 Colgate-Palmolive India reported a 12.2% year-over-year increase in revenue from operations, reaching INR 1,705.7 crore for the quarter ended September 30, 2026.
💰 Net profit grew 4.2% to INR 342 crore, demonstrating resilient profitability despite macroeconomic headwinds in the Indian consumer market.
🦷 The toothpaste portfolio achieved high-single-digit volume growth, bolstered by the premium range and the launch of Colgate MaxFresh.
⚠️ EBITDA margin declined to 28% from 31% as increased spending on brand building and premiumisation outpaced earnings growth in the quarter.
💸 Gross margin expanded by 40 basis points to 69.6%, indicating effective pricing power despite rising commodity costs.
📅 The company's board approved an interim dividend of INR 24 per share for fiscal 2026-27, payable starting November 19, 2026.
🏢 Management plans to mitigate commodity-cost volatility through cost savings initiatives and calibrated pricing strategies moving forward.
📈 Bullish signals
📈Colgate-Palmolive India delivered a strong quarterly performance with net profit rising 4.2% year over year to INR 342 crore.
📈Revenue from operations surged 12.2% to INR 1,705.7 crore, driven by double-digit sales growth in the core toothpaste portfolio.
🦷The company successfully launched Colgate MaxFresh and expanded its premium range, contributing to high-single-digit volume growth.
💸Gross margins improved by 40 basis points to 69.6%, reflecting effective cost management and pricing strategies.
📅The board approved a substantial interim dividend of INR 24 per share, signaling confidence in future cash flows.
📉 Risk factors
⚠️EBITDA margin contracted to 28% from 31% due to higher brand-building and premiumisation spending that outpaced earnings growth.
💰Operating costs and investment spending grew faster than earnings, temporarily dampening overall profitability despite revenue expansion.
Article
Colgate-Palmolive India reported robust financial performance for the quarter ended September 30, 2026, driven by double-digit sales growth and a strong profit beat. Net profit rose 4.2% year over year to INR 342 crore, while revenue from operations increased 12.2% to INR 1,705.7 crore. The company's toothpaste portfolio delivered high-single-digit volume growth, supported by the premium range and the Colgate MaxFresh product line.
Despite the top-line strength, operating efficiency faced headwinds as higher spending on brand building and premiumisation squeezed the EBITDA margin to 28% from 31%. Gross margins expanded by 40 basis points to 69.6%, but management noted that operating costs and investment spending grew faster than earnings. The company plans to address commodity-cost volatility through cost savings and calibrated pricing while continuing to invest in products and advertising.
The board approved an interim dividend of INR 24 per share for fiscal 2026-27, with payments scheduled to begin on November 19, 2026. Shareholders recorded on November 2, 2026, are eligible for this payout. This announcement follows the company's strong quarterly results and reflects its commitment to returning value to shareholders while navigating input cost pressures in the Indian consumer staples market.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Colgate-Palmolive Co (NYSE:CL) reported strong top and bottom line growth for its first quarter of 2026, with organic sales growth accelerating from the previous quarter driven primarily by improved volume performance in emerging markets, particularly the Asia Pacific region. The company achieved volume and pricing growth across all four product categories and four out of five divisions, excluding the impact of an exit from the private label pet food segment. This acceleration was led by regions where Colgate-Palmolive holds higher market share and scale advantages, with specific highlights in China, India, Mexico, and Brazil within the Asia Pacific and Latin America territories. The Hill's Pet Nutrition segment also delivered impressive performance through solid organic growth, innovation, and market share gains. Despite these strengths, North America continued to lag in volume and mix; however, CEO Noel Wallace noted that interventions within the H&W business are yielding results and that a strategy reset involving brand interventions, innovation, and improved execution is expected to drive improvement as new products and shelf resets take effect.
The earnings call highlighted significant headwinds related to cost inflation, with management stating that increased raw material and packaging costs have led to a reduced expectation for gross margins for the year. Specifically, the company faces a challenging environment with an additional $300 million impact on its operations from raw materials and logistics. CFO Stan Sutula detailed that this $300 million impact is composed of approximately two-thirds from raw materials and one-third from logistics, driven by significant increases in oil byproducts (with crude oil assumed at around $110) and overall logistics costs. Furthermore, higher tariffs are particularly impacting the North American operations. CEO Noel Wallace also mentioned that emerging markets will remain a key growth driver due to strong execution in omnichannel platforms and demand generation efforts, especially in regions like the Philippines and Thailand which performed well.
To address these cost pressures and drive efficiency, Colgate-Palmolive announced a strategic growth and productivity program with an annualized savings target ranging from $200 million to $300 million, with the majority of the realized savings focused in 2027 and 2028. The company is investing in innovation, data, analytics, digital capabilities, and AI to enhance its overall business performance and market share. Management indicated that while gross margins are expected to be pressured by raw material costs and tariffs, they remain confident in their earnings guidance range due to flexibility in delivering the bottom line through regular productivity programs affecting both cost of goods sold and SG&A, as well as through Premiumization efforts and innovation. The release date for these highlights was May 01, 2026, and GuruFocus detected two warning signs associated with the stock.
📈 Q1 2026 sales grew organically, led by Asia Pacific volume improvements.
🌍 Emerging markets drove expansion while North America faced volume headwinds.
📈 Colgate-Palmolive reported accelerated organic sales growth in Q1 2026, driven primarily by volume improvements in Asia Pacific.
📊 Growth was achieved across all four business categories and four of five divisions, excluding the private label pet food exit.
🌍 Emerging markets led the expansion, with significant contributions from high-market-share regions like Asia Pacific and Latin America.
💰 Key financial metrics including gross profit, operating profit, EPS, and free cash flow all demonstrated year-over-year growth.
🎯 The company set a strategic savings target of $200 million to $300 million annually, with the majority realized in 2027 and 2028.
⚠️ GuruFocus analysis has flagged two warning signs associated with Colgate-Palmolive (CL).
🐾 The Hill's Pet Nutrition segment delivered solid organic growth through innovation and market share gains.
📉 Rising raw material and packaging costs have pressured gross margins, leading to reduced annual expectations.
🌎 North America volume performance lagged in Q1 due to sluggish conditions in categories like Hawley & Hazel and China.
💸 The company faces approximately $300 million in additional cost impacts from raw materials and logistics, partly due to oil prices around $110.
🛡️ Management plans to offset these inflationary pressures through regular productivity programs, premium innovation, and RGM efforts.
🤖 Colgate is investing heavily in data analytics, digital capabilities, and AI to enhance operational efficiency and market share.
🌏 Asia Pacific growth was driven by strong performance in India and China, with mid-single-digit growth in the Chinese Colgate business.
📈 Latin America continues to execute well with strong demand generation in key markets like Mexico and Brazil.
🛒 Competitive pressure is increasing as rivals ramp up couponing and promotional activities to defend market share.
📅 The earnings call highlights were released on May 1, 2026, with Q1 results showing resilience despite headwinds.
📉 Management warned of continued margin pressure from tariffs and high commodity costs, particularly in the North America region.
🔄 A strategy reset involving brand interventions and better execution is underway for the underperforming North American market.
💼 Both CEO Noel Wallace and CFO Stan Sutula confirmed confidence in maintaining earnings guidance despite cost volatility.
🏭 The annualized savings program aims to boost operating margins as the $200-$300 million target is gradually implemented over time.
📉 Gross margin compression is expected to persist through 2026 and potentially into 2027 due to high input costs.
Bullish Signals
Organic sales growth accelerated from the fourth quarter, driven by improved volume performance particularly in Asia Pacific.
Volume and pricing growth were achieved across all four categories and four of five divisions.
Emerging markets led sales growth with strong contributions from high market share regions like Asia Pacific and Latin America.
The Hill's Pet Nutrition segment demonstrated impressive performance with solid organic growth and strong execution in innovation and market share gains.
Gross profit, operating profit, EPS, and free cash flow all experienced growth for the quarter.
Management maintains its top and bottom line guidance despite facing gross margin pressures from cost inflation.
Colgate-Palmolive is implementing a strategic growth program targeting annualized savings of $200 million to $300 million, focused on 2027 and 2028.
The company is investing in innovation, data, analytics, digital, and AI to enhance capabilities and drive market share improvement.
Asia Pacific growth was driven by strong execution in China, India, Philippines, and Thailand across omnichannel platforms.
Risk Factors
Significant increases in raw material and packaging costs, including an additional $300 million impact from oil byproducts and logistics, have reduced gross margin expectations for the year.
North America continues to lag in volume and mix despite interventions being in place, requiring time to show improvement.
The company faces heightened competitive pressure with increased couponing and promotional activities from rivals, threatening market share stability.
Gross margins are expected to be further pressured by higher raw material costs and new tariffs, particularly impacting operations in North America.
Cost inflation is described as a 'challenging' environment where the company must rely on productivity initiatives to offset pressures while maintaining guidance.
Colgate-Palmolive announced on Friday it expects approximately USD300 million in additional raw material and logistics expenses for the year due to Middle East conflict disruptions, joining rivals like Unilever and Procter & Gamble citing supply chain issues. Despite these warnings, shares rose 3 percent after the company beat first-quarter sales expectations of USD5.22 billion with actual net sales reaching USD5.32 billion and adjusted earnings per share of 97 cents. The firm plans to offset costs through a cost-savings program targeting USD200-300 million in savings by 2027 and continued price hikes via premium products. While international demand remained steady, North America volume fell 3.2 percent as budget-conscious shoppers sought lower-priced alternatives. Colgate reaffirmed its annual forecasts but warned that volatile macroeconomic conditions and slower category growth are likely to persist into 2026.
`, no `thought` tags in final output.
2. **Analyze the Input Content:**.
Headline: Colgate-Palm.
`.
2. **Analyze the Content:**
* **Headline:** ME conflict: Colgate-Palmolive warns of USD300m cost hit.
* **Key Fact 1:** Colgate expects ~USD300 million additional raw material/logistics expenses due to Middle East conflict.
* **Key Fact 2:** Shares rose 3% in early trading after beating Q1 sales/profit expectations.
* **Key Fact 3:** Quarterly net sales were $5.32 billion (beat estimates of $5.22 billion).
* **Key Fact 4:** Adjusted EPS was 97 cents (beat estimates by 2 cents).
* **Key Fact 5:** Cost-savings program aims for $200-300 million savings by 2028, mostly from 2027.
Bullish Signals
Shares rose 3% after beating Q1 sales and profit expectations.
Net sales hit $5.32B, exceeding analyst estimates of $5.22B.
Adjusted EPS of 97 cents beat estimates by 2 cents.
Demand for products remained steady despite price hikes.
Colgate reaffirmed annual sales and profit forecasts.
Risk Factors
Colgate faces $300M in extra raw material and logistics costs.
Rising commodity prices may suppress global consumer spending.
Price hikes could limit growth among value-conscious shoppers.
North America volume fell 3.2% as buyers seek cheaper options.
Volatile macro conditions and slow category growth persist through 2026.
Bullish Signals
Shares rose 3 percent in early trading after the company beat first-quarter sales and profit expectations.
The company reported quarterly net sales of $5.32 billion, exceeding average analysts' expectations of USD5.22 billion.
Adjusted earnings per share of 97 cents surpassed estimates by 2 cents.
Demand for Colgate's oral, personal care and household products remained steady despite price hikes.
Colgate reaffirmed its annual sales and profit forecasts.
Risk Factors
Colgate expects USD300 million in additional raw material and logistics expenses for the year.
Rising costs may weigh on global consumer spending due to higher commodity prices.
Analysts caution that raising prices while consumers are value-conscious could limit growth.
North America segment volume fell 3.2 percent as shoppers choose lower-priced alternatives.
Company warns volatile macroeconomic conditions and slower category growth will persist into 2026.
Colgate-Palmolive Company reported its Q1 2026 earnings, with performance primarily driven by accelerated volume growth in emerging markets, particularly the Asia Pacific region, where strong global brands are leveraging scale advantages. Management attributed this broad-based growth to sustained high advertising investment and an omnichannel demand generation model designed to maintain brand salience. In China, strategic interventions within the Hawley & Hazel business are beginning to yield results through accelerated innovation and improved omnichannel execution. However, North America performance remained sluggish due to delayed shelf resets and late-quarter innovation launches, though the company expects sequential improvement following a strategy reset involving brand interventions and better retailer execution.
The Hill's Pet Nutrition business significantly outperformed its flat market, propelled by double-digit growth in the Prescription Diet segment and enhanced supply chain flexibility. This segment remains resilient as pet owners prioritize health efficacy despite inflationary pressures, while the company is gaining share in wet food, cat food, and small paws segments. Conversely, gross margin expectations for the year were lowered from 'up' to 'down' due to resin and petrochemical inflation, with guidance assuming approximately $300 million in incremental raw material and logistics costs driven by oil prices projected at $110 per barrel. The company estimates that costs related to private label pet food exits will taper off by Q2 and vanish by the second half of the year.
To mitigate these challenges, Colgate-Palmolive is utilizing Revenue Growth Management (RGM) and AI-driven promotional tools to sustain profit growth in a volatile macroeconomic environment. The Strategic Growth and Productivity Program (SGPP) scope has expanded to $550 million, now expected to deliver $200 million to $300 million in total savings, primarily realized in 2027 and 2028, with the timeline fixed through 2028. Future pricing strategies will focus on innovation-led premium value propositions to justify higher price points. Logistics costs are projected to rise nearly 10%, impacting both ocean and land freight and being reflected in SG&A rather than gross margin, while North America faces tariff pressures expected to normalize later in the year as oil byproducts are anticipated to increase more than 20% year-on-year.
📈 Accelerated volume growth in Asia Pacific drove Q1 2026 performance despite North America slowdowns.
⚠️ Company faces $300M cost headwinds from inflation but expects relief by year-end H2.
💰 Expanded SGPP program targets $200–300M savings to fund long-term strategic initiatives through 2030.
📈 Colgate-Palmolive's Q1 2026 performance was anchored by accelerated volume growth in emerging markets, particularly within the Asia Pacific region.
📢 Management credits sustained high advertising investment and an omnichannel demand generation model for broad-based growth and brand salience.
🤖 The company is leveraging Revenue Growth Management (RGM) and AI-driven promotional tools to sustain profit growth amidst a volatile macroeconomic environment.
💊 Strategic interventions in the Hawley & Hazel business in China are delivering dividends through accelerated innovation and improved omnichannel execution.
🌽 North America performance remained sluggish due to delayed shelf resets and late-quarter innovation launches, with management expecting sequential improvement via a strategy reset.
🐾 The Hill's Pet Nutrition business outperformed a flat market driven by double-digit growth in the Prescription Diet segment and improved supply chain flexibility.
⚠️ Guidance assumes significant cost headwinds including approximately $300 million in incremental raw material and logistics costs driven by oil prices projected at $110 per barrel.
📉 The company lowered its gross margin expectations for the year to 'down' versus the prior 'up' outlook due to resin and petrochemical inflation.
⏳ Management expects the negative impact from the private label pet food exit to taper off to 20 to 30 basis points in Q2 and vanish by the second half of the year.
🛒 Future pricing actions will increasingly be innovation-led, focusing on premium value propositions to justify higher price points to consumers facing compounded inflation.
💰 The Strategic Growth and Productivity Program (SGPP) is expected to deliver $200 million to $300 million in total savings over the term of the program.
🛠️ The SGPP program scope was expanded to $550 million as teams identified more opportunities to simplify operations and enhance efficiency.
🏢 North America gross margins are currently pressured by a lack of tariff relief compared to the prior year, though this impact is expected to normalize as the year progresses.
🚢 Logistics costs are projected to rise nearly 10%, impacting both ocean and land freight, which will be reflected in SG&A rather than gross margin.
👀 Management flagged potential consumer sensitivity to compounded inflation and high energy prices over the next 6 to 9 months as a key variable to monitor.
📊 The $300 million cost headwind is split roughly two-thirds on raw materials and one-third on logistics, with oil byproducts expected to be up more than 20% year-on-year.
🔧 Management is proactively building these costs into operating unit strategies to ensure they maintain investment levels despite margin pressure.
⚙️ The increased savings target resulted from better-than-expected execution and the identification of new ways to simplify structure through spans and layers.
📅 The program timeline remains fixed through 2028, with savings intended to fund 2030 strategic initiatives and support bottom-line growth.
💎 The super-premium and Prescription Diet segments remain resilient because pet owners prioritize health efficacy even during inflationary periods.
🍖 While the dry dog food segment is currently suffering, Hill's is gaining share in wet food, cat food, and small paws segments.
Bullish Signals
Accelerated volume growth was anchored in emerging markets, particularly Asia Pacific, where strong global brands provide significant scale advantages.
The Hill's Pet Nutrition business significantly outperformed a flat market, driven by double-digit growth in the Prescription Diet segment and improved supply chain flexibility.
The Strategic Growth and Productivity Program (SGPP) scope expanded to $550 million as teams identified new opportunities to simplify operations, with savings expected to fund 2030 strategic initiatives.
The negative impact from the private label pet food exit is projected to taper off to 20 to 30 basis points in Q2 and vanish by the second half of the year.
North America is undergoing a 'strategy reset' involving brand interventions and better execution with key retailers, with management expecting sequential improvement in volume performance.
The super-premium and Prescription Diet segments remain resilient because pet owners prioritize health efficacy even during inflationary periods, allowing for premium value propositions.
While dry dog food faces headwinds, Hill's is gaining share in wet food, cat food, and small paws segments, demonstrating segment diversification strength.
Risk Factors
North America performance remained sluggish due to delayed shelf resets and late-quarter innovation launches, indicating ongoing execution challenges despite expected sequential improvement.
The company lowered its gross margin expectations for the year from 'up' to 'down', reflecting significant headwinds from resin and petrochemical inflation.
Guidance assumes approximately $300 million in incremental raw material and logistics costs driven by oil prices projected at $110 per barrel, which will pressure operating margins.
Logistics costs are projected to rise nearly 10%, impacting both ocean and land freight, further adding to SG&A pressures rather than being absorbed by gross margins.
North America gross margins face ongoing pressure from a lack of tariff relief compared to the prior year, although management expects this to normalize over time.
Management flagged potential consumer sensitivity to compounded inflation and high energy prices over the next 6 to 9 months as a key variable that could negatively impact demand.
Strategic interventions in the Hawley & Hazel business in China are still paying dividends but require continued investment, and North America volumes remain sluggish until execution improves.
Colgate-Palmolive reported a strong first quarter for fiscal 2026, driven by accelerated organic sales growth and improved volumes across its global operations. This growth was primarily led by emerging markets, particularly in the Asia-Pacific region, including China and India, where management noted mid-single-digit growth in oral care despite broader market headwinds. CEO Noel Wallace highlighted broad-based progress across geographies and categories, with specific praise for Hawley & Hazel's execution following recent intervention strategies and the early adoption of dual tube technology innovations.
However, the company faced margin pressure due to elevated input costs. Management maintained its full-year guidance for organic sales growth and earnings per share but lowered gross margin expectations by approximately 10 percentage points. This adjustment embeds an assumption of roughly $300 million in additional raw material costs, alongside oil prices projected near $110 per barrel for the remainder of the year. CFO Stan Sutula detailed that these incremental costs are split between raw materials and logistics, with key drivers including spending on petrochemicals and fats which is expected to rise more than 20% year-over-year.
To address sluggish volume performance in North America, where growth lags behind other regions, the company announced a strategy reset focused on brand interventions, accelerated innovation, and improved promotional execution with retailers. The updated Strategic Growth & Productivity Program aims to generate $200–$300 million in annualized savings by 2027–2028 to fund these growth initiatives. While logistics costs will impact SG&A rather than gross margin directly, the combined pressure from higher raw material prices and increased spending requires careful management to maintain the company's outlook for single-digit EPS growth.
📈 Strong organic sales growth driven by Asia-Pacific and emerging markets like China and India.
🧼 Oral care volumes are sluggish globally while North America executes a brand strategy reset.
💰 Management lowered gross margin guidance due to ~$300M in higher raw material costs.
📈 Colgate-Palmolive opened fiscal 2026 with strong top- and bottom-line growth driven by accelerated organic sales and improved volumes.
🌏 Volume performance was particularly strong in Asia-Pacific and emerging markets, led by China and India which are the region's two largest markets.
🧼 Oral care category volumes remain sluggish globally, including specific softness in China and Australia, though execution improvements were noted at Hawley & Hazel.
🛡️ Management maintained full-year guidance for organic sales growth and EPS but lowered gross margin expectations due to higher input costs.
💰 Approximately $300 million of additional raw material and logistics costs are embedded in the updated full-year guidance alongside an oil price assumption near $110/barrel.
📉 North America continues to lag on volume and mix, prompting a strategy reset involving brand interventions, faster innovation, and better promo execution.
🛠️ The Strategic Growth & Productivity Program now targets $200–$300 million of annualized savings concentrated in 2027–2028 to fund growth initiatives.
🦷 CEO Noel Wallace described toothpaste as a strategic growth opportunity and stated the company plans to step up investments in North America despite competitor couponing.
✨ Early signs from late-quarter innovations in home care and personal care were described as encouraging, with "dual tube technology" highlighted for oral care.
💸 CFO Stan Sutula noted that spending on key drivers like oil byproducts and resins is expected to be up more than 20% year-on-year for the full year.
🚢 Logistics costs are up nearly 10%, affecting both ocean and land freight, though these impacts affect SG&A rather than gross margin directly.
⚖️ Management plans to offset the incremental cost impact through revenue growth management (RGM) and productivity across the entire P&L.
📉 Analysts are being advised to reflect the lower gross margin assumptions in their valuation models while maintaining confidence in the EPS outlook range.
🐕 The company grew both volume and pricing in all four categories in four of five divisions when excluding the private label pet food exit.
🚀 Asia-Pacific strength was specifically tied to progress in the Philippines, Thailand, and Malaysia alongside strong performance in China and India.
⏱️ Some first-quarter volume dampening was attributed to delayed shelf resets and shipments of new products that came later than expected.
🔄 The updated guidance embeds oil assumptions around $110/barrel for the remainder of the year, up from previous expectations due to market volatility.
📊 Gross profit margin assumptions now include roughly two-thirds of the incremental impact relating to raw materials and one-third to logistics.
👩💼 Chairman, President and CEO Noel Wallace stated that broad-based execution drove volume acceleration versus the fourth quarter across geographies.
Bullish Signals
Strong top- and bottom-line growth opened fiscal 2026.
Organic sales accelerated, led by Asia-Pacific and China.
All four categories saw volume and pricing growth.
Hawley & Hazel improved via dual tube innovation.
Core China business delivered mid-single-digit growth despite flat market.
Company expects sequential North America volume improvement soon.
Aggressive home care innovation shows encouraging early signs.
Toothbrushes perform well; toothpaste is a strategic growth opportunity.
Full-year outlook maintained for organic sales growth and EPS.
Risk Factors
Gross margin guidance cut due to $300M added costs.
Oil price assumptions adjusted up to $110/barrel.
North America lags volume growth despite emerging market gains.
China core business faces flat or declining markets.
Australian results weaker than expected.
U.S. competitiveness threatened by competitor couponing.
Logistics costs projected to rise nearly 10%.
Raw material spending increases over 20% YoY.
Lower gross margins may trigger earnings estimate cuts.
New product shipment delays dampened Q4 volume.
Bullish Signals
Colgate-Palmolive opened fiscal 2026 with strong top- and bottom-line growth driven by accelerated organic sales and improved volumes.
Organic sales growth accelerated from the fourth quarter, primarily led by performance in Asia-Pacific and emerging markets like China, India, the Philippines, Thailand, and Malaysia.
The company achieved volume and pricing growth in all four categories across four of its five divisions when excluding private label pet food exit.
Asia-Pacific contributed to global volume acceleration with broad-based execution and continued progress at Hawley & Hazel.
Hawley & Hazel is executing better against intervention strategies, showing improvement through dual tube technology innovation and improved omni-channel execution including Douyin.
The core Colgate business in China delivered mid-single-digit growth despite a flat to declining market, describing results as generally positive.
Despite North America volume lags, the company expects sequential improvement moving forward following a strategy reset focused on brand interventions and accelerated innovation.
Management is taking a much more aggressive stance on innovation in home care and personal care with early signs described as encouraging.
Toothbrush business continues to perform very well while toothpaste is identified as a strategic growth opportunity.
The company maintains its full-year outlook for organic sales growth and EPS, offsetting higher raw material costs through productivity initiatives and RGM.
Risk Factors
Colgate-Palmolive lowered its gross margin expectations due to increased raw material and packaging costs, embedding approximately $300 million of additional costs into guidance.
The company's oil assumption for the remainder of fiscal year 2026 was adjusted upward to roughly $110/barrel, which impacts cost structures significantly.
North America continues to lag on volume growth despite recent acceleration in emerging markets, with a strategy reset and significant work still required to address mix issues.
The core Colgate business in China faces a flat to declining market environment, creating headwinds even after achieving mid-single-digit growth.
Australian performance was softer than anticipated, indicating potential weakness in that key geographic region.
Competitiveness in the U.S. oral care category is threatened by increased couponing activity from at least one competitor, necessitating stepped-up investments.
Logistics costs are projected to rise nearly 10% for the full year, affecting both ocean and land freight expenses.
Raw material spending is expected to be up more than 20% year-on-year for the full year due to volatility in oil byproducts, resins, petrochemicals, fats, and oils.
Management explicitly advised analysts to reflect the lower gross margin in their models, which could lead to downward revisions on earnings estimates.
Shipment delays for new products and shelf resets dampened first-quarter volume, though management noted this was temporary.
Colgate-Palmolive has announced a planned succession for its Chief Legal Officer, with longtime executive Jennifer M. Daniels set to retire in 2026 after serving in the role since 2014. In connection with this retirement, the Board of Directors elected Executive Vice President and Deputy Chief Legal Officer Betsy Fishbone to succeed Daniels as Chief Legal Officer and Secretary effective June 1, 2026. Following her departure from the legal leadership position, Daniels will assume the new title of Vice Chair as of the same date, a move designed to ensure an orderly transition within the company’s legal function.
Analyst commentary on the stock provided by TipRanks notes that the most recent rating for Colgate-Palmolive is a Buy with a price target of $102.00. However, Spark’s AI Analyst offers a Neutral score driven primarily by the company’s strong cash-flow generation and durable revenue base. This positive outlook is partially offset by concerns over an elevated balance sheet, which features high leverage compared to very thin equity, as well as weak technical indicators that weigh on the rating. The analysis also highlights mixed valuation metrics, including a reasonable yield but negative P/E, while earnings call commentary supports steady execution in Hills and emerging markets despite meaningful near-term uncertainty and a wide guidance range.
The article further contextualizes Colgate-Palmolive as a global consumer products company operating in the household and personal care industry, renowned for its oral care, personal hygiene, and home cleaning brands. The firm focuses on everyday consumer staples and maintains a broad international presence across both developed and emerging markets. While the leadership transition represents an internal structural change, these corporate developments occur alongside broader market dynamics mentioned in the accompanying content, including fluctuating oil prices impacting Canadian energy stocks, upcoming CPI data, and analyst upgrades for various equities as earnings season approaches.
🏛️ Jennifer Daniels will retire in 2026 as Chief Legal Officer and Secretary.
⚖️ Betsy Fishbone succeeds her as CL Officer starting June 1, 2026.
📈 TipRanks AI rates stock Neutral despite strong cash flow and revenue.
💰 Analyst consensus targets Colgate stock at $102.00 with a Buy rating.
🏛️ Colgate-Palmolive announced that longtime Chief Legal Officer and Secretary Jennifer M. Daniels plans to retire in 2026.
⚖️ Effective June 1, 2026, Executive Vice President and Deputy Chief Legal Officer Betsy Fishbone will succeed Daniels as Chief Legal Officer and Secretary.
🔄 On the same date, Jennifer M. Daniels will transition to the role of Vice Chair to ensure an orderly leadership succession in the legal function.
💰 Current analyst consensus rates Colgate-Palmolive stock as a Buy with a price target of $102.00.
📊 TipRanks' AI Analyst provides a Neutral rating for CL, citing strong cash flow and revenue against high leverage and technical weakness.
🍂 The company operates globally in household and personal care, known for oral care, hygiene, and home cleaning brands across developed and emerging markets.
Bullish Signals
Leadership transition ensures orderly succession with Betsy Fishbone starting June 1, 2026.
Analysts rate Colgate-Palmolive (CL) stock as a Buy with a $102.00 price target.
Strong cash-flow generation and durable revenue base drive positive analyst sentiment.
Focus on consumer staples across markets provides stable foundation for consistent performance.
Strong execution in Hills' and emerging markets supports operational stability.
Risk Factors
CLO Jennifer Daniels retires in 2026, creating leadership transition uncertainty.
Analyst Spark rates CL Neutral due to weak indicators and negative P/E.
High leverage versus thin equity elevates balance-sheet financial vulnerability risk.
Wide earnings guidance range signals near-term meaningful earnings volatility uncertainty.
Bullish Signals
The upcoming leadership transition for Chief Legal Officer Jennifer M. Daniels ensures an orderly succession with Betsy Fishbone appointed effective June 1, 2026, to maintain continuity in the legal function.
Analysts rate Colgate-Palmolive (CL) stock as a Buy with a $102.00 price target, indicating confidence in the company's long-term prospects.
The company demonstrates strong cash-flow generation and maintains a durable revenue base, which are key drivers of its positive analyst sentiment.
Colgate-Palmolive's focus on everyday consumer staples across both developed and emerging markets provides a stable foundation for consistent performance.
Strong execution in Hills' and emerging markets was highlighted during the earnings call, supporting the company's operational stability despite near-term uncertainties.
Risk Factors
Chief Legal Officer Jennifer M. Daniels plans to retire in 2026, creating uncertainty around leadership continuity during the transition period.
Analyst Spark rates CL as Neutral due to weak technical indicators and a negative P/E valuation, highlighting mixed investor sentiment.
The company carries elevated balance-sheet risk characterized by high leverage versus very thin equity, increasing financial vulnerability.
Earnings guidance shows meaningful near-term uncertainty with a wide guidance range, signaling potential earnings volatility.
Consumers nationwide may qualify for compensation under a $2.9 million class action settlement involving Tom's of Maine toothpaste. The settlement arises from a lawsuit alleging deceptive and misleading business practices related to the manufacturing, marketing, and sale of specific products, which followed a 2024 U.S. Food and Drug Administration inspection that identified safety standard compliance issues at a Maine manufacturing facility. Colgate-Palmolive, the parent company of Tom's of Maine, has denied the allegations but agreed to settle the matter to avoid litigation costs and risks.
Eligibility for claims extends to individuals who purchased Tom's toothpaste products for personal use between November 21, 2020, and March 6, 2026. Consumers uncertain about their status can contact the settlement administrator via email at [email protected]. Claims can be submitted online through the designated settlement website or by mailing a completed claim form. Physical forms are available by requesting them via phone at 1-877-315-6779 or by mail to P.O. Box 2897, Portland, Oregon, 97208-2897.
Regarding potential compensation, payouts will be determined by the volume of claims submitted and the evidence provided. Individuals filing without proof of purchase may receive an amount equal to the average retail price of one product, while those submitting proof of purchase could qualify for a full refund covering up to three products. All claims must be filed online or postmarked no later than July 6, 2026. A final approval hearing is scheduled for September 10, 2026, in federal court, with final payments contingent upon settlement approval and potential timelines extensions for any appeals or additional proceedings.
✅ $2.9M settlement reached over deceptive Tom's of Maine business practices after FDA safety flags.
📅 Eligible claimants include purchases made between Nov 21, 2020 and March 6, 2026 for personal use.
💳 Proof of purchase allows full refunds up to three products; no proof offers average retail compensation.
⏰ Submit claims online or via mail by July 6, 2026 final deadline.
🦷 A $2.9 million class action settlement has been reached regarding deceptive business practices involving Tom's of Maine toothpaste products.
🏭 The lawsuit originated after a 2024 FDA inspection flagged safety compliance concerns at the company's Maine manufacturing facility.
💰 Colgate-Palmolive, Tom's parent company, denied the allegations but agreed to settle to avoid litigation costs and risks.
📅 Eligibility is extended to consumers who purchased products for personal use between Nov. 21, 2020, and March 6, 2026.
🏠 Consumers can file claims by visiting the settlement website or mailing request forms to the administrator in Portland, Oregon.
📞 Claimants may also contact the settlement administrator directly via phone at 1-877-315-6779 for assistance.
💸 Those submitting without proof of purchase may receive compensation equal to the average retail price of one product.
💳 Purchasers who provide proof of documentation may qualify for a full refund covering up to three products.
📆 All claim submissions must be postmarked or submitted online by the July 6, 2026 deadline.
⚖️ A final approval hearing is scheduled to take place on Sept. 10, 2026, in federal court.
🏛️ Payments are contingent upon final settlement approval and could face delays if appeals or legal proceedings occur.
Bullish Signals
Claims due July 6, 2026; approval hearing Sept. 10, 2026.
Risk Factors
Settlement stems from lawsuit over deceptive Tom's toothpaste practices.
FDA inspection revealed safety non-compliance at Maine manufacturing facility.
Colgate denied allegations but settled to avoid litigation costs and risks.
Payments depend on settlement approval, timeline may extend due to appeals.
Consumers without proof of purchase get average retail price, not full refund.
Final hearing set for Sept 10, 2026, with claims deadline July 6, 2026.
Bullish Signals
Claims must be submitted by July 6, 2026, with a final approval hearing scheduled for Sept. 10, 2026.
Risk Factors
The settlement stems from a lawsuit alleging 'deceptive and misleading business practices' related to the manufacturing, marketing and sale of certain Tom's toothpaste products.
A 2024 inspection by the U.S. Food and Drug Administration raised concerns about conditions at a Maine manufacturing facility not being in compliance with safety standards.
Colgate-Palmolive denied the allegations but agreed to settle to avoid the costs and risks of litigation, suggesting underlying legal vulnerabilities.
Payments will only be distributed if the settlement is approved, and the timeline could be extended if there are appeals or additional legal proceedings.
Consumers who file without proof of purchase may receive an amount equal to the average retail price of one product, which may fall short of a full refund.
The final approval hearing is scheduled for Sept. 10, 2026, with a claims deadline of July 6, 2026, creating a long waiting period and uncertainty for claimants.
On World Health Day, Colgate-Palmolive (India) Limited has launched an initiative to make preventive dental care more accessible across India through free dental check-ups. The campaign is built on the slogan 'There is no health without Oral Health' and aims to transition the public from reactive repair to proactive care. This effort expands upon the company's 2024-25 Oral Health Movement, which facilitated over 4.5 million dental screenings nationwide. The initiative addresses a critical gap in oral health statistics, noting that nine out of ten Indians suffer from oral health issues, while only 9% visit a dentist annually. Contributing factors to this crisis include consumption habits like increased intake of sweets and processed foods, along with poor brushing hygiene where 80% of urban Indians do not brush at night and half of the rural population does not brush daily.
To overcome access barriers, Colgate has partnered with the Indian Dental Association (IDA) to onboard 63,000 dentists, allowing consumers to scan a QR code on any Colgate toothpaste pack for a brief assessment and receive a personalized Dental Screening Report. This platform connects users with participating dentists in their vicinity for free consultations. Recognizing that rural India suffers from one of the poorest dentist-to-patient ratios at 1:250,000, necessitating travel of 50-150 kilometers to find a professional, Colgate has integrated virtual consultation options via Bajaj Health to ensure physical distance does not prevent access. Gunjit Jain, Executive Vice President, Marketing at Colgate-Palmolive (India) Limited, stated that the program removes friction by offering free screening and consultations with either 63k partner dentists or through virtual visits.
Dr. Ashok Dhoble, Hon. Secretary General of the IDA, highlighted that providing free dentist access at this massive scale acts as a powerful catalyst for change across the country. The initiative seeks to bridge the access gap by embedding dentist resources into everyday consumer touchpoints. Gunjit Jain noted that addressing the crisis of apathy where one in ten Indians visits a dentist despite high prevalence of dental problems, the goal is universal impact through unprecedented reach. Colgate-Palmolive (India) Limited continues its commitment to science-led innovations and community well-being, aiming for a sustainable future with programs like Colgate Bright Smiles, Bright Futures® that empower communities and enhance children's oral health.
🦷 Colgate-Palmolive launches free dental check-ups across India via QR codes on toothpaste packs.
📉 90% of Indians suffer oral health issues while only 9% visit dentists annually.
🌐 Platform connects users with dentists or offers virtual care for rural areas.
🦷 Colgate-Palmolive (India) is launching a free dental check-up initiative to improve preventive oral health care access nationwide.
📊 The program follows on the success of the past year, having already facilitated over 4.5 million dental screenings across India.
😟 Statistics highlight that 90% of Indians suffer from oral health issues due to poor consumption habits and low brushing rates.
👨⚕️ Only 9% of Indians visit a dentist annually, creating a significant gap between the population needing care and those receiving it.
🔗 Colgate has partnered with the Indian Dental Association (IDA) to onboard 63,000 dentists for access through QR codes on toothpaste packs.
📱 Users can scan QR codes on any Colgate pack to complete an assessment and receive a personalized dental screening report.
🏥 The platform connects consumers with participating dentists in their specific pincode for free physical consultations.
🚜 To address poor rural dentist availability, the initiative offers virtual consultation options via a partnership with Bajaj Health.
📍 Rural India faces a dentist-to-patient ratio of 1:250,000, forcing patients to travel up to 150 km for basic care.
💬 Gunjit Jain, EVP at Colgate-Palmolive (India), stated the goal is shifting consumers from "reactive repair" to "proactive care."
🤝 Dr. Ashok Dhoble of the IDA described the free access initiative as a powerful catalyst for change across the country.
🌐 The platform integrates technology and everyday consumer touchpoints to bridge the gap between common people and professional dental care.
✨ This initiative is part of Colgate-Palmolive's broader Oral Health Movement aimed at driving long-term shifts toward early diagnosis.
🏢 Colgate-Palmolive (India) Limited is recognized as the market leader in oral care within the country with a focus on innovation.
♻️ The company also continues sustainability efforts, including reducing plastic waste and promoting recyclability in its manufacturing facilities.
Bullish Signals
Colgate facilitated over 4.5M dental screenings nationwide in 2024-25.
63,000 dentists onboarded via Indian Dental Association.
Dental professional shortage limits offline partner network effectiveness in rural areas.
Deep-rooted apathy and lack of awareness persist despite significant investment efforts.
4.5 million screenings in 2024-25 cannot meet demand from 9 out of 10 Indians.
High sugary food consumption requires dietary intervention beyond dental check-ups.
Virtual consultations depend on Bajaj Health integration adding technical complexity.
Bullish Signals
Colgate-Palmolive (India) has successfully facilitated over 4.5 million dental screenings nationwide in 2024-25, demonstrating the scalability of its Oral Health Movement.
The company has onboarded 63,000 dentists through the Indian Dental Association, creating one of the country's largest consumer touchpoints for expert guidance.
By integrating virtual consultations with Bajaj Health, Colgate bridges the gap in rural dentist availability, allowing access without requiring travel between 50-150 Kms.
The initiative offers free dental check-ups and personalized screening reports via QR codes on Colgate toothpaste packs, removing friction and making preventive care accessible to all Indians.
Colgate-Palmolive is recognized as the market leader in Oral Care in India, committed to delivering sustainable and profitable growth for its shareholders.
The company has made significant strides in sustainability efforts, including reducing plastic waste, conserving water and energy at manufacturing facilities.
Through its Colgate Bright Smiles, Bright Futures® program, Colgate enhances children's oral health while fostering financial and digital literacy for women.
Risk Factors
Severe dentist scarcity persists in rural India with a dentist-to-patient ratio of only 1:250,000, forcing residents to travel 50-150 Kms to access care.
Only 9% of Indians visit a dentist annually despite the fact that 9 out of 10 Indians suffer from oral health issues.
The initiative relies heavily on QR code scanning via Colgate toothpaste packs, creating dependency on product packaging rather than independent digital infrastructure.
Low adoption rates for night brushing (80% of urban Indians) and daily brushing (half of rural population) suggest the free access may not address fundamental behavioral barriers.
Rural India faces a critical shortage of dental professionals that limits the effectiveness of Colgate's offline partner network, forcing reliance on virtual consultations.
The article cites an 'abysmally low rate' of dentist visits in India, highlighting a deep-rooted crisis of apathy and lack of awareness despite significant investment.
While Colgate claims 4.5 million screenings were facilitated in 2024-25, the sheer scale of need (9/10 Indians with issues) implies significant unserved demand remains.
High consumption of sweets and processed foods is identified as a primary driver for oral health decline, suggesting dietary intervention may be necessary beyond dental check-ups.
Virtual consultation partnerships depend on Bajaj Health integration, adding operational complexity and potential technical dependency to the service delivery model.
Colgate-Palmolive CEO Noel Wallace delivered remarks on the company's evolution and strategic direction during a program celebrating America's 250th anniversary. In this video interview, which has a duration of two minutes and one second, Wallace reflects on how Colgate-Palmolive transitioned from a small soap business into a global leader in oral care over its history. The discussion highlights the company's journey spanning approximately 220 years as it reinvents itself while honoring its legacy as an American icon.
Wallace emphasized that this transformation has been driven primarily by three core elements: innovation, purpose, and a commitment to improving health for both the United States and the global community. The video was uploaded and made available on April 2, 2026, at 4:13 PM EDT, according to the metadata associated with the content. Throughout the segment, the focus remains on the company's long-term strategy to maintain its relevance and impact in a rapidly changing marketplace while adhering to its founding principles.
The coverage includes sharing options via Facebook, Twitter, LinkedIn, and email, underscoring the significance of the CEO's message for a broad audience. The interview captures Wallace's perspective on sustaining growth and maintaining the brand's trust through continuous adaptation and dedication to public health initiatives worldwide. This feature aims to inspire viewers by connecting Colgate-Palmolive's commercial success with its broader social mission in the context of American history.
🦷 Colgate-Palmolive celebrates its 220-year legacy as a global oral care leader.
🌍 Growth driven by innovation, purpose, and health commitments in U.S. and globally.
📅 CEO Noel Wallace shares vision via video interview on April 2, 2026.
🦷 Colgate-Palmolive CEO Noel Wallace reflects on the company's evolution from a small soap business to a global oral care leader during America's 250th anniversary.
🌍 The company is driving this growth through innovation, purpose, and a commitment to improving health both in the U.S. and globally.
📅 This reflection was shared via a video interview published on April 2, 2026, as part of America: 250 Years Bold initiatives.
💼 CEO Noel Wallace emphasizes the importance of reinventing an American icon while honoring its 220-year history.
⚡ The focus remains on continuing to evolve the brand's legacy through modern innovation and purpose-driven strategy.
Bullish Signals
CEO rebrands 220-year-old brand.
Evolution to global oral care leader.
Bullish Signals
VideoObject.
Colgate-Palmolive CEO Noel Wallace on reinventing a 220-year-old American icon.
The article outlines the company's successful evolution from a small soap business into a global leader in oral care, driven by innovation and purpose.
Risk Factors
Article content is overwhelmingly positive with no explicit negative points or risks mentioned regarding Colgate-Palmolive.
Colgate-Palmolive is preparing for a significant shareholder vote on May 8, 2026, where investors must choose between supporting current management or demanding major governance changes. The primary debate revolves around the separation of the Chairman and CEO roles and the removal of Diversity, Equity, and Inclusion criteria from the director nomination process; both proposals have been recommended for rejection by the company's board. Despite this internal tension, the company is emphasizing its financial strength and operational stability, particularly in its international Oral Care and Hill's Pet Nutrition segments which drive its 2030 strategic plan.
Financially, the company continues its long-term commitment to returning value through dividends, having recently increased its quarterly payout to $0.53 per share for a distribution scheduled on May 15, 2026, marking the 63rd consecutive year of dividend growth. In trading activity, shares have risen nearly one percent to reach approximately €73.68, though they remain trading around 15% below their 52-week high set in April 2025. On the legal front, the company received a positive ruling on March 26 when a federal judge dismissed an antitrust lawsuit, removing a potential overhang from its quarterly results.
Institutional investors are also monitoring the situation closely with mixed signals regarding their positions. While The Vanguard Group made an administrative reporting change that is viewed as neutral rather than a sale of stock, other major institutional managers like Rempart Asset Management have recently increased their holdings in the company. These moves suggest that while governance concerns are high among activist shareholders and retail investors, large-scale capital remains invested, signaling confidence in the underlying business performance despite the strategic disagreements at the corporate level.
🗓 Annual meeting scheduled for May 8, 2026, on governance and HR policies.
💰 Company raised quarterly dividend to $0.53, marking the 63rd consecutive year of growth.
⚖ Shareholders debate separating Chairman/CEO roles and removing DEI criteria from nominations.
✅ Board recommends voting against both proposed shareholder measures regarding governance reforms.
📈 Shares rose ~1% to €73.68 despite trading below their 52-week high.
🗓️ A contentious annual meeting is scheduled for Colgate-Palmolive on May 8, 2026.
⚖️ Shareholders must decide between endorsing current management or supporting governance reforms.
👔 The central debate focuses on the concentration of power at the top and HR policy direction.
💰 Despite tensions, the company raised its quarterly dividend to $0.53 per share.
📈 This payout marks the 63rd consecutive year of dividend growth for the firm.
🏪 Operational focus remains on international growth via Oral Care and Hill's Pet Nutrition segments.
⚖️ Two specific shareholder proposals are challenging the current board structure.
✂️ Investor John Chevedden proposes separating the roles of Chairman and CEO.
🚫 The National Legal and Policy Center urges removing DEI criteria from director nominations.
✅ The Board of Directors has recommended voting against both proposed measures.
⚖️ A federal judge dismissed an antitrust lawsuit involving Colgate-Palmolive on March 26.
🏦 This legal ruling removes a significant near-term overhang for the business.
📊 Institutional investors are adjusting stances, with Vanguard making an internal reporting change.
🐂 Other institutions like Rempart Asset Management have recently expanded their holdings.
💶 The share price recently increased nearly one percent to reach €73.68.
📉 However, the equity still trades approximately 15% below its 52-week high from April 2025.
Bullish Signals
Colgate-Palmolive raised quarterly dividend to $0.53 per share.
Company marks 63rd consecutive year of dividend growth.
Judge dismissed antitrust lawsuit on March 26.
Ruling removes legal overhang and stock uncertainty.
Major investors like Rempart expanded holdings significantly.
Risk Factors
Pivotal annual meeting approaches on May 8, 2026.
Top power concentration remains a major investor concern.
Activists urge removing DEI criteria to create conflict.
Board recommends voting against governance proposals indicating tension.
Stock trades 15% below April 2025 high showing skepticism.
Bullish Signals
Colgate-Palmolive recently announced an increase in its quarterly dividend to $0.53 per share, marking the 63rd consecutive year of dividend growth.
This reliable payout, scheduled for distribution on May 15, 2026, underscores a long-term commitment to shareholder returns amidst the governance debate.
The company received favorable legal news as a federal judge dismissed an antitrust lawsuit in which Colgate-Palmolive was named a defendant on March 26.
This ruling alleviates a near-term legal overhang for the business and removes uncertainty from the stock outlook.
Major institutional investors like Rempart Asset Management have recently expanded their holdings in the company, signaling confidence in its long-term prospects.
The Vanguard Group's recent internal reporting change is viewed by market observers as an administrative move rather than a share sale, preventing unnecessary panic.
The equity trade price of €73.68 shows a modest increase of nearly one percent in recent trading, demonstrating resilience despite the looming annual meeting.
Risk Factors
A contentious annual meeting is approaching on May 8, 2026, where shareholders face a pivotal decision regarding governance reforms versus maintaining the current management strategy.
Significant concentration of power at the top remains a concern for investors, as highlighted by John Chevedden's proposal to separate the Chairman and CEO roles.
The National Legal and Policy Center is urging the removal of Diversity, Equity, and Inclusion (DEI) criteria from the director nomination process, creating potential internal conflict and reputational risk.
The Board of Directors has recommended shareholders vote against both governance proposals, indicating high tension between management and activist investors.
Although dividends are growing, the stock trades approximately 15% below its 52-week high recorded in April 2025, suggesting lingering market skepticism about recent performance.
Colgate Total has announced a strategic partnership with the Mumbai Indians to serve as their Dental Performance Partner ahead of the 2026 season, aiming to integrate oral health into the team's broader athletic preparation framework. This collaboration centers on the launch of the PLOT (Performance Linked Oral Test) initiative, a comprehensive screening system designed to proactively assess and maintain peak dental health among players. The program is built on scientific evidence indicating that the mouth serves as a gateway for germs that can enter the body, trigger inflammation, and hinder recovery, thereby impacting stamina and on-field endurance. To support this, Dr. Moez Khakiani will act as lead clinician, conducting advanced intraoral scanning technology assessments alongside WHO-based oral health evaluations to identify potential fitness impediments before the high-intensity season begins.
Gunjit Jain, EVP of Marketing at Colgate-Palmolive India, emphasized that while athletes traditionally focus on sleep and nutrition, oral health remains a critical "hidden edge" in sports that is now being made mainstream through this partnership. The initiative leverages Colgate Total's patented formula, which the company states is three times more effective at fighting germ buildup than previous formulations and helps prevent eight different dental problems. By mandating dental tests for all players on the squad, the program aims to create a shift in the performance paradigm where prevention becomes a foundational element of elite sport strategy, aligning with Mumbai Indians' philosophy that marginal gains are essential to competitive success.
Ben Langley, Head of Sports Science and Medicine at Mumbai Indians, reinforced the partnership's alignment with their science-led approach to player health, noting that systemic inflammation caused by oral germs can directly impact musculoskeletal recovery and cardiovascular efficiency. This collaboration underscores Colgate-Palmolive's commitment as a market leader in the Indian oral care sector, highlighting its broader corporate goals of sustainability, water conservation, and community well-being through programs like Colgate Bright Smiles. The announcement marks a significant step toward recognizing systemic wellness as a critical determinant of performance, reinforcing the belief that peak athletic output starts with proactive prevention of dental health issues.
🤝 Colgate Total partners with Mumbai Indians for the 2026 season as Dental Performance Partner.
🦷 Dr. Khakiani will lead advanced intraoral scanning screenings using PLOT performance frameworks.
⚠ Mouth germs cause inflammation that slows muscle recovery and reduces athletic stamina.
🤝 Colgate Total has established a new partnership with the Mumbai Indians to serve as their Dental Performance Partner for the upcoming 2026 season.
🦷 The collaboration centers on the PLOT (Performance Linked Oral Test) initiative, designed to integrate oral health screenings into the team's performance framework.
⚠️ Scientific evidence suggests that germs in the mouth can cause systemic inflammation, which slows muscle recovery and impacts overall stamina.
📋 Lead clinician Dr. Moez Khakiani will conduct comprehensive dental screenings using advanced intraoral scanning technology for Mumbai Indians players.
💊 Colgate Total's patented formula is highlighted as being 3X more effective at fighting germ buildup compared to other oral care products.
🗣️ Gunjit Jain of Colgate-Palmolive India described oral health as the "hidden edge" in sports that elevates people's lives and performance.
📉 Ben Langley, Mumbai Indians Head of Sports Science & Medicine, emphasized that marginal gains from preventing systemic inflammation are crucial for winning.
🚀 The partnership represents a paradigm shift towards preventive care, mandating dental tests for all players to prevent issues before they affect fitness.
🌍 Colgate-Palmolive positions itself as a sustainable growth company with a focus on science-led innovations in the Indian market.
📈 The initiative aims to encourage other sports teams to adopt similar protocols by making the "hidden edge" of oral health mainstream.
Bullish Signals
Colgate Total has secured a strategic partnership with Mumbai Indians as their official Dental Performance Partner ahead of the 2026 season, reinforcing its market leadership in India.
The new PLOT (Performance Linked Oral Test) initiative integrates advanced intraoral scanning technology and WHO-based assessments to proactively assess player health and enhance on-field endurance.
Dr. Moez Khakiani will lead comprehensive dental screenings for Mumbai Indians, utilizing superior Colgate Total formula which is scientifically proven to be 3X more effective at fighting germ build-up.
This partnership positions oral health as a critical determinant of athletic performance, helping the team gain marginal gains in recovery and cardiovascular efficiency.
Colgate-Palmolive (India) Limited maintains its status as the market leader in Oral Care in India while delivering sustainable, profitable growth for shareholders.
The company continues to advance sustainability through significant strides in reducing plastic waste, conserving water and energy, and empowering women with financial and digital literacy.
Risk Factors
Colgate-Palmolive (India) Limited is a market leader but faces increasing scrutiny and risk as this press release is an advertorial, indicating potential bias in reported metrics such as the '3X more effective' germ-fighting claims which lack independent verification within the text.
The partnership with Mumbai Indians for the 2026 season relies heavily on proprietary intraoral scanning technology from Colgate, creating a risk of market-specific dependency if competitors replicate this screening framework.
While positioning dental health as a 'hidden edge', the initiative admits that germs in the mouth can cause systemic inflammation and slow recovery, suggesting that athletes may have undiagnosed oral health issues that could lead to reduced performance or injury during the high-intensity 2026 season.
Despite claims of 'sustainable, profitable growth' and environmental improvements, the article highlights a specific shift in focus to oral care partnerships rather than broader R&D investments, potentially limiting diversification against market competition.
The initiative mandates dental tests for all players, which could expose the Mumbai Indians franchise to privacy concerns or reputational damage if significant systemic health issues are uncovered among their roster before the season begins.
Colgate Total's formula is marketed as 'the very best' with specific patent claims, yet the article provides no comparative data against other toothpastes, making the efficacy claims vulnerable to competitor challenges or consumer skepticism.
The press release emphasizes reducing plastic waste and energy conservation at facilities but does not quantify these environmental metrics or disclose any potential compliance risks regarding future sustainability regulations in India.
AN (ANI) explicitly disclaims responsibility for the content, relying solely on PRNewswire provided by the company, which introduces a layer of third-party risk verification that is absent from standard journalistic coverage.
Gunjit Jain, EVP Marketing, notes that while other athletes optimize sleep and nutrition, oral health remains an 'hidden edge', implying that a gap in current player performance management exists, suggesting the company may benefit disproportionately if competitors fail to adopt similar preventive measures soon.
The initiative relies on WHO-based assessments but does not specify which version or year, leaving ambiguity about whether the standards align with the most current medical guidelines relevant for elite sports performance.
Schaeffer's has identified Colgate-Palmolive (NYSE:CL) as one of its top 15 stock picks for 2026, citing technical indicators that suggest a bullish trend channel with strong support near the $75 level. This price point coincides with significant put open interest and a 38.2% Fibonacci retracement of historical lows from 2000 to September 2024 highs, a level from which the stock historically rebounds. Market sentiment appears mixed, with 14.30 million shares sold short nearing all-time highs while ten of the 21 analysts covering the stock maintain hold or worse ratings; however, options data indicates optimism with a put/call open interest ratio of 2.03 and high volume ratios for calls across major exchanges like the CBOE and ISE.
Analyst price targets for Colgate-Palmolive remain dispersed, ranging from US$86 to US$105, reflecting varying assessments of the company's 2030 strategic plan against sector headwinds. Major banks like Bank of America and Goldman Sachs raised their targets to US$105 and US$100 respectively, driven by confidence in the product pipeline and emerging market exposure, while Piper Sandler upgraded its rating with a US$88 target despite acknowledging valuation pressures. Conversely, houses like TD Cowen lowered targets to US$86 due to challenging large-cap staple conditions, and Wells Fargo maintains an Equal Weight at US$100 but notes risks to sales growth are already priced in.
For 2026, Colgate-Palmolive issued earnings guidance projecting net sales growth between 2% and 6%, with organic sales expected to grow 1% to 4% before excluding the approximately 20 basis point impact from exiting its private label pet food business. Management anticipates double-digit earnings per share growth alongside gross profit margin expansion, supported by higher advertising spend and restructuring programs involving US$200m to US$300m over three years aimed at AI-driven digital transformation. However, the company faces specific risks including consumer caution in key markets such as North America, Brazil, and India, along with elevated raw material costs and intensified competition in categories like pet food and local bran.
📈 Colgate-Palmolive is a top 2026 pick with bullish sentiment despite mixed analyst ratings.
💰 Support sits at $75 while fair value models suggest a target near $97.
🚀 Growth drivers include emerging markets exposure, pet food exit benefits, and AI initiatives.
📊 Colgate-Palmolive is identified as one of Schaeffer's top 15 stock picks for 2026, highlighted in a quarterly analysis published on December 23.
📉 The stock trades near the lower boundary of a long-term bullish trend channel and its 128-month moving average, which has supported lows since October 2004.
🛡️ Strong support is established at the $75 price level, marking a 38.2% Fibonacci retracement from previous highs that historically triggered rebounds.
💰 Technical indicators show peak put open interest at $75 and an unwinding of negativity, with call/put volume ratios signaling bullish sentiment across major exchanges.
📉 Short interest is approaching all-time highs with 14.30 million shares sold short, while the majority of analysts maintain hold or worse ratings.
💸 Analyst price targets remain mixed, ranging from $86 trimmings by Piper Sandler and TD Cowen to $105 lifts by BofA and Goldman Sachs.
📈 Major financial institutions including Wells Fargo, JPMorgan, Citi, and Morgan Stanley have refreshed or raised targets in early 2026 to reflect broad interest in the company's 2030 plan.
💡 Key drivers for growth include Colgate Palmolive’s SGPP program, product pipeline expansion, emerging markets exposure, and reduced drag from its pet food exit.
📈 Management provided earnings guidance for 2026 projecting net sales growth between 2% to 6%, with organic sales growth expected at 1% to 4%.
💰 The company anticipates gross profit margin expansion on a GAAP basis alongside double-digit earnings per share growth driven by increased advertising spend.
🔄 A share buyback program announced in March 2025 has seen the company repurchase over 5.8 million shares for approximately $516 million, with no further activity since October.
📈 The modeled fair value was nudged higher from $96.68 to roughly $97.21, reflecting adjustments in revenue growth expectations and net profit margins.
⚠️ Identified risks include consumer caution in key markets like North America, Brazil, and India, along with higher raw material and packaging costs.
🤖 Strategic initiatives focus on AI, digital transformation, and productivity programs including up to $300 million in restructuring costs over three years.
Bullish Signals
Strong support at $75 with bullish trend channel.
BofA and Goldman Sachs lift price targets to $105 and $100.
Emerging markets show improvement with attractive current valuation.
Management expects double-digit EPS growth by 2026.
Completed buyback of 5.89 million shares worth $515.76M.
AI and digital initiatives drive oral care premiumization.
Restructuring plans target $200m-$300m productivity gains over three years.
Major banks raise targets including Wells Fargo, JPMorgan, Citi, Morgan Stanley, TD Cowen, Barclays and UBS through early 2026.
Risk Factors
Wells Fargo holds an Equal Weight rating with a $100 target.
TD Cowen downgraded the stock to a $86 target in January.
Net sales growth forecast is narrow at 2% to 6% for 2026.
Exiting private label pet food business creates a 20 basis point drag.
Rising raw material costs threaten to compress profit margins.
Bullish Signals
Colgate-Palmolive is trading near the lower rail of a long-term bullish trend channel and has strong support at $75, with historical rebound patterns from this level. Multiple major banks including BofA and Goldman Sachs lifted their price targets to $105 and $100 respectively, citing confidence in the company's 2030 plan and product pipeline. Analyst consensus shows early signs of improvement in emerging markets and reduced reliance on a stretched US market, making current valuation attractive with potential upside. Management expects earnings per share growth in double digits for 2026 alongside gross profit margin expansion and net sales growth of 2% to 6%. The company successfully completed the buyback of 5.89 million shares worth $515.76 million under its share repurchase program announced on March 20, 2025. Product strategy focuses on expansion and premiumization in core oral care with AI and digital transformation initiatives intended to free up resources for growth. The company's restructuring plans include $200m to $300m over three years aimed at improving productivity and supporting long-term execution of its 2030 plan. Analysts from multiple houses including Wells Fargo, JPMorgan, Citi, Morgan Stanley, TD Cowen, Barclays and UBS have refreshed or raised targets through early 2026.
Risk Factors
Wells Fargo has an Equal Weight rating at a US$100 target, with earlier moves to Underweight at US$86 reflecting concern over recent risks to sales growth and valuation.
TD Cowen downgraded the target to US$86 in January, citing a challenging setup for large cap staples due to limited volume improvement and muted pricing power.
The company expects net sales growth of only 2% to 6% for 2026, with minimal positive impact from foreign exchange included in that range.
Organic sales growth guidance is narrow at 1% to 4% for 2026, partly due to the approximately 20 basis point drag from exiting the private label pet food business.
Key risks include consumer caution in major markets like North America, Brazil, and India, which could dampen volume recovery.
Rising costs in raw materials and packaging threaten to compress profit margins despite the company's cost-cutting initiatives.
Competition is intensifying in key categories such as pet food and local brands, putting pressure on market share and pricing power.
Federal Judge Andrea Wood in Chicago has ruled that Colgate-Palmolive must face two lawsuits alleging its mouth rinse packaging misleads parents into believing children under six can use these products safely. The court dismissed a separate lawsuit concerning Colgate toothpaste, distinguishing the two cases by noting that while Colgate's rinse labels featured bright colors and kid-friendly flavors like Bubble Fruit to suggest safety, the toothpaste labels explicitly instructed children aged 2 to 6 to use only pea-sized amounts of fluoride toothpaste. Judge Wood stated that reasonable consumers might not know where to draw the line for rinses given prominent labeling such as "kids" or "children's," and was unpersuaded by Colgate's argument that users should check back labels containing FDA warnings. Plaintiffs argued that U.S. health authorities warn against fluoride rinses for children under six and that fluoride can be harmful if swallowed, a risk exacerbated by packaging making excessive use appear safe.
In related legal developments, federal Judge Casey Pitts in San Jose dismissed with prejudice a proposed class action lawsuit against PepsiCo regarding its Gatorade protein bars. The plaintiffs had accused PepsiCo of falsely marketing the bars as beneficial for muscle rebuilding and scientifically backed, while containing 28 grams of added sugar and only 20 grams of protein per bar. They claimed the product violated consumer protection laws by portraying itself as healthy when it exceeded the American Heart Association's recommended daily sugar limit for women at 25 grams. PepsiCo argued that consumers would not expect its Gatorade bars, especially flavors like Chocolate Chip, to be marketed as low in sugar or healthy, and Judge Pitts noted the case was previously permitted to proceed after finding potential consumer confusion over the company's self-proclaimed science-backed claims.
Separately, a Texas judge rejected Kenvue's request to dismiss a lawsuit by Texas Attorney General Ken Paxton accusing the company of falsely marketing Tylenol as safe for pregnant women. Paxton alleges Kenvue violated the state's Deceptive Trade Practices Act by concealing risks, including scientifically unproven claims linking acetaminophen use during pregnancy to autism. Kenvue contended that labeling for painkillers like Tylenol falls under FDA jurisdiction and argued that prohibiting marketing consistent with current science infringed on free speech rights under the First Amendment. In another case, federal Judge Manish Shah in Chicago dismissed a lawsuit against Mondelez International over Clif bars labeled "climate neutral certified," finding no issue with the labels which reflected certification from the Change Climate Project for Clif Kid Zbar and Zbar Protein products.
🔍 Federal Judge ruled Colgate must face two lawsuits over misleading fluoride rinse packaging for children under six.
⚠ Bright colors and "kids" labels confuse parents despite FDA warnings against fluoride rinses for toddlers.
🤝 Similar legal challenges target P&G, Mondelez, Kenvue, and others regarding deceptive product claims and safety risks.
🔍 Federal Judge Andrea Wood ruled in Chicago that Colgate-Palmolive must face two lawsuits over misleading mouth rinse packaging for children under 6.
🚫 The judge dismissed a similar lawsuit concerning toothpaste, noting that labels expressly instructed pea-sized amounts for toddlers between ages 2 and 6.
⚠️ Plaintiffs argue that bright colors and flavors like Bubble Fruit on Colgate rinse bottles imply safety to consumers despite FDA warnings against fluoride rinses for young kids.
⚖️ Judge Wood rejected Colgate's defense that shoppers would understand over-the-counter drug labels, emphasizing the confusion caused by prominent "kids" or "children's" wording.
🤝 Procter & Gamble and Mondelez International face similar legal challenges regarding their packaging of fluoride products and climate-neutral claims respectively.
🧪 The FDA recommends pea-sized amounts of toothpaste for children aged 2 to 6 but warns that fluoride mouth rinses should generally not be used by those under 6.
📉 Colgate-Palmolive is based in New York, while Judge Wood described the situation as consumers likely unsure where to draw the safety line on rinse products.
🧠 Michael Connett, a lawyer for plaintiffs in the Colgate case, stated that these rulings should prompt manufacturers to stop promoting unsafe fluoride usage.
🥤 PepsiCo had its Gatorade protein bars lawsuit dismissed with prejudice after Judge Casey Pitts found no evidence of false marketing despite higher sugar content than advertised.
💊 Texas Judge LeAnn Rafferty rejected Kenvue's motion to dismiss a state Attorney General lawsuit accusing the company of concealing autism risks in Tylenol during pregnancy.
🌍 Mondelez International lost its proposed class action against them over claims that Clif bars were deceptively labeled as "climate neutral certified."
⚖️ All three cases involve significant consumer protection implications and potential liability for major multinational corporations like Colgate, PepsiCo, Kenvue, and Mondelez.
Bullish Signals
Judge Shah dismissed Mondelez class action with prejudice.
Court upheld Clif Kid Zbar protein label claims.
PepsiCo dismissed Gatorade lawsuit involving dozens of brands.
Judge Shah dismissed the proposed class action lawsuit with prejudice against Mondelez International, meaning the case cannot be brought again.
The court found nothing wrong with labels for Clif Kid Zbar and Zbar Protein products that reflected a certification from the Change Climate Project.
PepsiCo successfully had a lawsuit accusing it of falsely marketing Gatorade protein bars dismissed by U.S. District Judge Casey Pitts in San Jose, California, resolving a case involving dozens of its brands including Fritos, Lay's, Mountain Dew and Ocean Spray.
Procter & Gamble reached a similar resolution in January regarding its Crest toothpaste labeling investigation following Colgate's September agreement to introduce new packaging.
Risk Factors
A federal judge ruled in favor of Colgate-Palmolive on toothpaste claims but maintained the company must face two lawsuits alleging misleading packaging for mouth rinse products intended for children under 6.
Judges rejected Colgate's defense that consumers would recognize rinses as drugs requiring label checks, citing prominent 'kids' or 'children's' labeling and bright, candy-like flavors such as Bubble Fruit and Silly Strawberry.
Class action plaintiffs allege the misleading packaging could lead young children to consume unsafe amounts of fluoride, which is harmful if swallowed, disregarding health authority warnings against rinses for children under 6.
Procter & Gamble and other competitors like Perrigo and Sanofi face similar lawsuits regarding their fluoride product packaging, indicating a broader industry vulnerability to deceptive labeling claims.
A Texas judge rejected Kenvue's request to dismiss an Attorney General lawsuit accusing the company of falsely marketing Tylenol as safe for pregnant women despite unproven links to autism risks.
Kenvue faces allegations of violating the Texas Deceptive Trade Practices Act by concealing potential risks to children when pregnant mothers use the painkiller, challenging its reliance on FDA labeling standards.
Although PepsiCo secured dismissal of a lawsuit regarding Gatorade protein bars, the case revealed concerns about 'fortified junk food' containing 28 grams of added sugar against a 25-gram daily limit for women.
The dismissal in Mondelez International's climate neutral certification case suggests that some labeling claims may be scrutinized, yet the specific outcome here was favorable to Mondelez, unlike the Colgate and Kenvue situations.
U.S. District Judge Jane Boyle has dismissed X Corp.'s antitrust lawsuit alleging that the World Federation of Advertisers and major brands like Mars, CVS Health, and Colgate-Palmolive engaged in an illegal boycott against Elon Musk's platform. Filed in 2024, the case claimed that advertisers collectively withheld billions of dollars in revenue through the Global Alliance for Responsible Media initiative, acting against their own self-interest to harm X. Judge Boyle ruled on Thursday in federal court in Dallas that X failed to demonstrate the necessary harm under federal antitrust laws required to proceed with the claim. The decision dismisses the case with prejudice, meaning it cannot be refiled.
Defendants argued that the advertisers made independent business decisions based on concerns over brand safety following Musk's 2022 takeover of the company, rather than coordinating a conspiracy. They maintained they were acting individually to avoid risks associated with the platform's environment after employees focused on maintaining a welcoming space for family-friendly brands were let go. Judge Boyle agreed with this assessment in her order, stating that the very nature of the alleged conspiracy does not state a valid antitrust claim, and thus the court had no hesitation in dismissing the action. Neither X Corp nor the World Federation of Advertisers provided immediate comments on the ruling upon request.
The dismissal effectively ends the legal challenge regarding these advertising boycotts, reinforcing the principle that independent commercial decisions by multiple entities, even if they result in significant revenue loss for one company, do not necessarily constitute an actionable antitrust violation without proof of concerted action. The companies involved deny any wrongdoing and view their departure from X as a strategic response to policy and brand safety changes rather than an illegal collective act. This development marks a significant legal setback for X Corp's efforts to seek remedies against its major advertisers.
⚖ Judge Boyle dismissed X's antitrust lawsuit against advertisers with prejudice.
📉 Court ruled X failed to prove necessary harm under federal laws.
🤐 The conspiracy claim was invalidated due to independent advertiser decisions.
💸 Case involves alleged withholding of billions in advertising revenue since 2024.
❌ X cannot refile this specific lawsuit following the Dallas court ruling.
👨⚖️ U.S. District Judge Jane Boyle dismissed X Corp's antitrust lawsuit against advertisers on Thursday in federal court in Dallas.
⚖️ The judge ruled that X failed to demonstrate it suffered any harm under federal antitrust laws necessary to sustain a claim.
❌ X Corp's lawsuit, filed in 2024, alleged that major companies like Mars and CVS Health conspired to withhold billions of dollars in advertising revenue.
🧠 Defendants argued the advertisers acted independently based on business decisions regarding brand safety rather than an illegal boycott.
🔥 Advertisers claimed they left X after Elon Musk's 2022 takeover, citing concerns over the platform's commitment to a family-friendly environment.
⚡ Judge Boyle stated that "the very nature of the alleged conspiracy does not state an antitrust claim."
📉 The court dismissed the case with prejudice, meaning X Corp cannot refile the same lawsuit in the future.
🤐 Neither X Corp nor the World Federation of Advertisers provided immediate comment requests on this ruling.
Bullish Signals
Judge Jane Boyle dismissed X Corp's antitrust lawsuit.
Court ruled X failed to show harm under federal laws.
Major advertisers Mars, CVS, and Colgate proved independent decisions.
Risk Factors
Judge Boyle dismissed X Corp antitrust lawsuit for lack of proven harm.
Major advertisers like Mars and CVS chose rivals over brand safety fears.
Ad revenue withheld via Global Alliance for Responsible Media remains disputed.
Defendants argued advertisers made independent decisions without acting in unison.
Bullish Signals
U.S. District Judge Jane Boyle dismissed X Corp's antitrust lawsuit with prejudice, signaling a decisive legal victory against the allegations of an illegal boycott.
The court ruled that X failed to show any harm under federal antitrust laws, effectively clearing the company of liability regarding the advertising revenue dispute.
Major advertisers including Mars, CVS Health, and Colgate-Palmolive successfully defended their positions by demonstrating independent business decisions rather than a coordinated conspiracy.
Risk Factors
X Corp's antitrust lawsuit was dismissed with prejudice by U.S. District Judge Jane Boyle because the company failed to demonstrate any harm under federal antitrust laws.
Major advertisers, including Mars, CVS Health, and Colgate-Palmolive, independently chose rival platforms due to concerns over brand safety following Elon Musk's 2022 takeover.
X Corp alleged that advertisers withheld billions of dollars in advertising revenue through the Global Alliance for Responsible Media initiative.
Defendants argued X failed to prove advertisers acted in unison rather than making individual business decisions regarding ad spending.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)